Total Payments
$84,258
2024 Payments
$73,300
Companies
50
Transactions
407
Medicare Patients
2,291
Medicare Billing
$230,929
Payment Breakdown by Category
Research$73,226 (86.9%)
Food & Beverage$6,440 (7.6%)
Travel$2,840 (3.4%)
Consulting$1,485 (1.8%)
Education$147.93 (0.2%)
Gifts$118.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $73,226 | 6 | 86.9% |
| Food and Beverage | $6,440 | 377 | 7.6% |
| Travel and Lodging | $2,840 | 15 | 3.4% |
| Consulting Fee | $1,485 | 1 | 1.8% |
| Education | $147.93 | 6 | 0.2% |
| Gift | $118.80 | 2 | 0.1% |
Payments by Type
Research
$73,226
6 transactions
General
$11,032
401 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $73,844 | 9 | $0 (2024) |
| Novo Nordisk Inc | $2,629 | 93 | $0 (2023) |
| Novo Nordisk AS | $1,538 | 7 | $0 (2019) |
| Medtronic MiniMed, Inc. | $1,483 | 20 | $0 (2020) |
| MannKind Corporation | $702.63 | 45 | $0 (2023) |
| Dexcom, Inc. | $486.82 | 25 | $0 (2023) |
| Amarin Pharma Inc. | $440.27 | 24 | $0 (2022) |
| ABBVIE INC. | $284.47 | 18 | $0 (2023) |
| Abbott Laboratories | $260.23 | 14 | $0 (2023) |
| Lilly USA, LLC | $173.78 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $73,300 | 9 | Eli Lilly and Company ($73,196) |
| 2023 | $1,224 | 35 | Eli Lilly and Company ($648.36) |
| 2022 | $874.61 | 55 | Novo Nordisk Inc ($247.00) |
| 2021 | $1,058 | 60 | Novo Nordisk Inc ($283.98) |
| 2020 | $889.20 | 47 | Amarin Pharma Inc. ($166.19) |
| 2019 | $5,105 | 62 | Novo Nordisk Inc ($1,550) |
| 2018 | $758.88 | 60 | Novo Nordisk Inc ($198.89) |
| 2017 | $1,048 | 79 | Novo Nordisk Inc ($246.48) |
All Payment Transactions
407 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,606.00 | Research |
| Study: A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $41,090.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,263.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,957.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,280.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $51.45 | General |
| 09/11/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: Diabetes | ||||||
| 07/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: DIABETES | ||||||
| 05/23/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: EndoVenous Therapies | ||||||
| 09/29/2023 | Eli Lilly and Company | — | — | In-kind items and services | $30.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/11/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $441.08 | General |
| 09/11/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $159.00 | General |
| 09/11/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $18.28 | General |
| 08/17/2023 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Spinal Cord Stimulator | ||||||
| 08/01/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: Diabetes | ||||||
| 07/26/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Diabetes | ||||||
| 07/23/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $38.80 | General |
| Category: Diabetes Care | ||||||
| 06/14/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Diabetes | ||||||
| 06/13/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Cardio-renal | ||||||
| 06/07/2023 | MannKind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: DIABETES MEDICINE | ||||||
| 05/23/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $26.87 | General |
| Category: Endocrinology | ||||||
| 05/23/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Diabetes Care | ||||||
| 05/16/2023 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Durable Pump | ||||||
| 05/10/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Rare Disease | ||||||
| 05/03/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $41,090 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $12,263 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $9,957 | 1 |
| A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | Eli Lilly and Company | $5,606 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $4,310 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 347 | 491 | $128,000 | $29,626 |
| 2022 | 8 | 646 | 1,020 | $242,858 | $67,180 |
| 2021 | 10 | 619 | 994 | $255,418 | $72,504 |
| 2020 | 10 | 679 | 1,014 | $228,542 | $61,619 |
Total Patients
2,291
Total Services
3,519
Medicare Billing
$230,929
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 167 | 251 | $83,332 | $19,018 | 22.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 67 | 120 | $11,040 | $2,792 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 38 | $8,892 | $1,726 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $5,580 | $1,555 | 27.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 16 | 18 | $5,976 | $1,519 | 25.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 23 | 23 | $5,060 | $1,463 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,020 | $1,021 | 17.0% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 11 | 15 | $2,100 | $532.39 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 191 | 358 | $118,856 | $32,164 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 151 | 213 | $49,842 | $13,553 | 27.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 106 | 224 | $20,608 | $5,806 | 28.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 58 | 58 | $16,588 | $4,236 | 25.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 44 | 51 | $11,934 | $3,542 | 29.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 38 | 41 | $9,020 | $3,274 | 36.3% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2022 | 39 | 56 | $7,840 | $2,396 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $8,170 | $2,210 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 210 | 433 | $143,538 | $39,418 | 27.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 113 | 152 | $35,392 | $9,652 | 27.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 87 | 161 | $14,812 | $4,359 | 29.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 51 | 51 | $14,586 | $4,328 | 29.7% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 45 | 49 | $10,780 | $4,204 | 39.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 43 | 53 | $12,358 | $3,322 | 26.9% |
| 95249 | Continuous monitoring of glucose in tissue fluid using sensor under skin | Office | 2021 | 29 | 52 | $7,280 | $2,327 | 32.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $6,868 | $1,973 | 28.7% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 14 | 15 | $5,820 | $1,771 | 30.4% |
About Dr. Dan Lender, MD
Dr. Dan Lender, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Rockwall, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760445274.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dan Lender, MD has received a total of $84,258 in payments from pharmaceutical and medical device companies, with $73,300 received in 2024. These payments were reported across 407 transactions from 50 companies. The most common payment nature is "" ($73,226).
As a Medicare-enrolled provider, Lender has provided services to 2,291 Medicare beneficiaries, totaling 3,519 services with total Medicare billing of $230,929. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Rockwall, TX
- Active Since 04/07/2006
- Last Updated 04/29/2020
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1760445274
Products in Payments
- Victoza (Drug) $1,527
- Minimed 670G System (Device) $1,422
- AFREZZA (Drug) $702.63
- Saxenda (Drug) $501.11
- Vascepa (Drug) $440.27
- Dexcom G6 Transmitter (Medical Supply) $287.67
- Ozempic (Drug) $225.63
- JARDIANCE (Drug) $208.22
- Wegovy (Drug) $164.39
- Omnipod (Device) $159.79
- NATPARA (Drug) $150.16
- BD NANO (Device) $134.68
- Synthroid (Drug) $121.92
- Tymlos (Biological) $106.42
- SYNTHROID (Drug) $105.90
- INVOKANA (Drug) $88.58
- V-GO (Device) $87.75
- Kerendia (Drug) $85.03
- DEXCOM CGM (Device) $79.51
- Rybelsus (Drug) $78.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.